Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-001984-62 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study seeks to show that interscalene injection of a small volume (<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB.
It's a prospective monocentric randomized controlled clinical trial in 2 parallel groups in double blind.
the study concerns patients undergoing arthroscopic shoulder surgery with ISB. The study seeks to show that interscalene injection of a small volume (<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB.
Randomization in one of the two arms:
Evaluation of diaphragmatic stroke by ultrasound and ventilatory function by spirometry and snip test before performing the ISB, then after installation of the ISB.
Performing the surgical procedure under general anesthesia assessment of postoperative analgesia and patient satisfaction during the following 48 hours.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group : ropivacaine 0.1% | Experimental | Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine |
|
| control group : ropivacaine 0.5% | Active Comparator | Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ropivacaine 0.5% Injectable Solution | Drug | Injectable solution of ropivacaine 0.5% |
|
| Measure | Description | Time Frame |
|---|---|---|
| Compare the occurrence of hemi-diaphragmatic paresis | Hemi diaphragmatic paresis is evaluated by quantifying the homolateral diaphragmatic stroke at interscalene block (ISB) by ultrasound analysis (measured in centimeter), during slow and deep inspiration. Diaphragmatic hemiparesis is defined as a decrease (at post-ISB time vs. pre-ISB time) of more than 25% of the diaphragmatic stroke during this slow and deep inspiration. | 1h after interscalene block |
| Measure | Description | Time Frame |
|---|---|---|
| Compare the frequency of hemi-diaphragmatic paralysis | Hemi-diaphragmatic paralysis refers to the absence of diaphragmatic movement (or paradoxical movement) in ultrasound during rest ventilation and slow, deep inhalation. | 1h after interscalene block |
| Compare intraoperative analgesia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arnaud ALLUIN, MD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Roger Salengro, CHU | Lille | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42244823 | Result | Verbeke AL, Jeanneteau A, Bellet J, Genin M, Cirenei C, Alluin A, Tavernier B. The diaphragm-sparing effect of interscalene block with a low-volume of ropivacaine 0.1% vs. 0.5%: A double-blind, controlled, randomised trial. Eur J Anaesthesiol Intensive Care. 2026 Apr 23;5(3):e0108. doi: 10.1097/EA9.0000000000000108. eCollection 2026 Jun. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012133 | Respiratory Paralysis |
| D053120 | Respiratory Aspiration |
| ID | Term |
|---|---|
| D012131 | Respiratory Insufficiency |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D010243 | Paralysis |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077212 | Ropivacaine |
| ID | Term |
|---|---|
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ropivacaine 0.1% Injectable Solution | Drug | Dilution of ropivacaine to the concentration of 0.1% |
|
|
Total consumption of sufentanil, and Analgesia Nociception Index values (ANI, MetroDoloris, France). |
| peroperative time |
| Compare postoperative analgesia | Duration of effective analgesia (defined as the period up to the first EVA > 3 (excluding PACU Consumption of morphine in PACU and analgesics within the first 24 hours. | 24 hours postoperatively |
| Compare the ventilatory function (spirometry and snip test). | Presence of a respiratory impairment detected by spirometry (Spiro-USB® device) and presence of a diaphragmatic impairment detected by snip test, (micro-RPM®). Ventilation impairment will be considered present if there is a decrease of at least 25% in vital capacity between the pre and post ISB. Diaphragmatic damage is defined as a decrease of at least 25% in the Snip-test values between the pre and post ISB. | 1h after interscalene block |
| Compare patient satisfaction | Evaluation of patient satisfaction by questionnaire at the patient's bedside or by telephone call within 24h-48h postoperatively. It is assessed on a numerical scale from 0 to 10 (0 being the lowest satisfaction value and 10 the highest value) | 24 to 48 hours postoperatively |
| Compare the contralateral diaphragmatic stroke | Evaluation of contralateral diaphragmatic compensation (diaphragmatic stroke in ultrasound, comparison of post-ISB time vs. pre-ISB time, expressed in %). | 1h after interscalene block |
| D009461 |
| Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
| D000588 |
| Amines |